We studied the effect of topically applied phenytoin on the healing of a decubitus ulcer in the sacral region of an immobile patient with stroke. Another similar, but smaller, ulcer was treated with conventional treatment only and served as a control. The ulcers were measured once a week and biopsies were taken from the margins before, 1 week and 2 weeks after commencing treatment with phenytoin. Clinically, phenytoin substantially accelerated the rate of healing. Microscopic examination of the biopsies showed increased lymphocytic infiltration of the phenytointreated lesion. Anti-CD31 immunohistochemistry revealed dense CD31+ lymphocytic infiltration and increased angiogenesis only in the phenytointreated lesion. Our findings suggest that phenytoin enhances wound healing by stimulating lymphocytic chemotaxis and up-regulation of angiogenesis.
Introduction
Approximately half of all patients taking the anti-epileptic drug phenytoin have gingival hyperplasia. 1 The exact mechanism by which phenytoin induces gingival hyperplasia is not clear, but gingival biopsies show infiltration of mononuclear cells in the connective tissue adjacent to the junctional epithelium. 2 In vitro, phenytoin induces production of mononuclear cell factors that stimulate quiescent human gingival fibroblasts to enter the S-phase, 3 and interleukin-1b production in human peripheral blood mononuclear cells. 4 Cytokines released from inflammatory cells may, therefore, be involved in pathogenesis of phenytoininduced lesions. 5 In the first controlled clinical trial, patients undergoing periodontal surgery who were pre-treated with oral phenytoin had less inflammation and pain, and accelerated healing, compared with those with similar surgical wounds and no pretreatment. 6 Several more recent clinical reports have suggested that topical phenytoin has an effect on the healing of traumatic wounds, 7,8 large abscess cavities, 9 trophic leprosy ulcers, 10 diabetic foot ulcers, 11 decubitus ulcers and a number of other chronic wounds. 12 The aim of our study was to evaluate, clinically and histologically, the effect of phenytoin on healing of decubitus ulcer in a patient with stroke.
Case report
A 58-year-old man was admitted to the neurology department for 'locked in' syndrome due to infarction at the mid-pontine level. He was alert, but had quadriplegia and was unable to communicate because of involvement of all efferent pathways. Within the first month of hospitalization he started to develop two pressure ulcers in the sacral region. All the necessary preventive measures for skin care were undertaken (flotation mattress, turning the patient side to side every 2 -3 h, wet-to-dry dressing, infusion of parenteral amino acids and topical antiseptic application), but the decubitus ulcers worsened.
On surgical debridement the ulcers were seen to extend to the periosteum of the sacrum. The ulcers were treated daily with local antiseptics and wet-to-dry dressings, but no evidence of tissue healing was noted during the following week.
The two elliptical ulcers were almost symmetrically located in the sacral region separated by a 2 cm band of healthy skin. The left ulcer was 6 × 9 cm and the right ulcer 9 × 12 cm.
We decided to treat the right ulcer (the larger ulcer) with topical application of phenytoin (250 mg [5 ml solution] daily) in addition to the standard care. The left ulcer was treated with antiseptic and dressings only and served as control. The dimensions of the two lesions were recorded weekly.
After 43 days of treatment with phenytoin, the right ulcer measured 2.5 cm 2 (1 × 2.5 cm) compared with 108 cm 2 at T0 and the left ulcer 7.5 cm 2 (1.5 × 5 cm) compared with 54 cm 2 at T0 (Fig. 1 ). The rate of healing of the right phenytoin-treated ulcer (2.45 cm 2 /day) was clearly more rapid than that of the left ulcer (1.08 cm 2 /day). (T2) after beginning treatment of the right ulcer with phenytoin. Fig. 1A shows the two ulcers at T0. Haematoxylin and eosin (H & E) sections were prepared from the biopsies taken from both lesions at T0, T1 and T2. In parallel with this, the angiogenic activity in tissue sections was studied immunohistochemically using the anti-CD31 monoclonal antibody (MoAb) and the alkaline phosphatase-antialkaline-phosphatase (APAAP) procedure. Briefly, sections were dewaxed, rehydrated and pre-digested with protease type XXIV for 20 min at 37 o C. JC70 (1:50; Dako, Glostrup, Denmark) was applied at room temperature for 30 min and washed in tris-buffered saline (TBS). Rabbit anti-mouse antibody 1 in 50 was applied for 30 min, followed by application of mouse APAAP complex 1 in 1 for 30 min. After washing in TBS, the last two steps were repeated for 10 min each. The sections were then stained by incubation at room temperature in New Fuchsin solution for 20 min.
BIOPSY SAMPLES AND ANALYSIS
The vascular density of the stained slides was assessed as follows: first the sections were scanned at low power (× 40 and × 100); counting was then done at the edge of the ulcer; three areas of high vascular density were chosen at × 100 and microvessel counting of these areas was done at × 200; and the final microvessel score was the mean of the vessel counts obtained from the three fields. Vessels with a clearly defined lumen or a well-defined linear vessel shape, but not single endothelial cells, were counted.
As JC70 MoAb also reacts with a specific lymphocytic CD31+ subpopulation, the degree of tissue infiltration by these cells was also examined.
Dense lymphocytic infiltration was noted in the T1 H & E sections of the phenytointreated right ulcer. This persisted in the other (T2) biopsy from this ulcer. In contrast, lymphocytic foci were only occasionally noted in biopsies from the left lesion.
Immunostained tissue sections from both lesions had similar vascular density of 140 -150 vessels per × 200 optical field at T0. CD31+ lymphocytic infiltration was minimal ( Fig. 2A) . At T1, the vascular density of the right phenytoin-treated ulcer rose sharply to 219 vessels per × 200 optical field (Fig. 2B) , and striking CD31+ lymphocytic infiltration was evident ( Fig. 2C) 
Discussion
Decubitus ulcers develop as a result of pressure and friction in patients with quadriplegia (independent of the cause of quadriplegia) and are more likely to occur when there is inadequate nutrition, in particular, protein intake. Typically, large decubitus ulcers are unresponsive to conventional treatment and this is one problem encountered during rehabilitation of patients with stroke. A topical agent that would enhance wound healing is therefore a continuing quest of medical science. Several clinical reports have suggested that topical application of phenytoin is effective in healing wounds, 8, 9 but the therapeutic dosage of topical phenytoin for this purpose has not been established. In most studies a thin layer of the powder was applied to the wound surface without further quantification. Systemic absorption following topical phenytoin therapy does not appear to be of significant consequence, even for very large wounds. 12 The side-effects of phenytoin are therefore probably of little significance in most wound healing applications.
The exact mechanism of action of phenytoin in wound healing is still unclear. Some researchers have shown that phenytoin accelerates wound healing by stimulating fibroblast proliferation, enhancing granulation tissue formation, inhibiting collagenase activity, promoting collagen deposition, decreasing bacterial contamination and reducing wound exudate production. 6, 8, 11, 13, 14 Increased angiogenesis following topical application of phenytoin has also been reported. 4 In our study, we observed acceleration in the rate of healing of a decubitus ulcer following topical application of phenytoin. This was objectively documented by weekly measurement of the phenytoin-and conservatively-treated ulcers; the latter, although smaller, healed more slowly. Examination of the H & E sections showed dense lymphocytic infiltration of the margins of the phenytointreated ulcer, but this cellular infiltrate was absent in the sections from the control ulcer.
Immunostaining confirmed a marked CD31+ lymphocytic presence exclusively in sections from the ulcer treated with phenytoin. The vascular density also increased sharply following phenytoin application. It seems therefore that phenytoin, by inducing local cytokine release (presumably from skin fibroblasts), contributes to the accumulation of lymphocytes and angiogenesis that accelerates the healing of the decubitus ulcers.
CD31 (platelet endothelial cell adhesion molecule-1) is involved in the adhesion of lymphocytes to the endothelium and transmigration into the extravascular space. 15 -18 Several studies also suggest that CD31+ lymphocytic infiltration is linked to increased angiogenesis in tumours and other conditions. 19 -21 Although cytokines released by these cells may be responsible for the angiogenic response, a direct differentiation of CD31+ cells to endothelial cells cannot be excluded. 22 The accumulation of CD31+ lymphocytes in the margins of healing wounds following application of phenytoin strongly supports the hypothesis that phenytoin-mediated angiogenic activity may involve activation of this specific lymphocytic subset.
Our study suggests that phenytoin is effective in decubitus ulcer healing and contributes to the healing process at several levels. The therapeutic value of phenytoin for treating non-healing ulcers with different causes should be investigated further in prospective clinical studies.
